Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2026)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Assets of -$330.3 million for Q4 2025, down 184.48% year-over-year from $391.0 million in Q4 2024, and down 184.48% quarter-over-quarter from $391.0 million in Q4 2024.
Powered by 
Analysis
Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2026) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Assets for 3 consecutive years, with -$330.3 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Telix Pharmaceuticals | 4.03 Bn | 3.74 Bn | - | 873.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 873.83 Mn |
| Dec 31, 2025 | 6.92 Mn |
| Dec 31, 2024 | 390.98 Mn |
| Dec 31, 2023 | 112.92 Mn |